FDA’s Complete Responses to Generic Drugmakers Continue to Outpace Fiscal 2017

Drug Industry Daily
The FDA continued to issue a larger number of complete response letters to generics manufacturers last month — dropping from a spike in October, but still higher than any single month in the previous fiscal year.

To View This Article:


Subscribe To Drug Industry Daily